MedTrace Logo

Crossover Trial for Nicotinamide Riboside in Subjective Cognitive Decline and Mild Cognitive Impairment

NCT04078178 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 61

Last updated 2024-11-29

Study results available
· View outcomes & findings →

Summary

In this research study we want to learn more about whether taking Niagen, a daily supplement containing a form of Vitamin B3, will improve cognitive function, mood, and daily activity in people with Subjective Cognitive Decline (SCD) or Mild Cognitive Impairment (MCI).

Conditions

Interventions

DIETARY_SUPPLEMENT

Niagen

Nicotinamide Riboside

DIETARY_SUPPLEMENT

Placebo Comparator

Placebo

Sponsors & Collaborators

  • Steven E Arnold, MD

    lead OTHER

Principal Investigators

  • Steven Arnold, MD · MGH

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
QUADRUPLE
Model
CROSSOVER

Eligibility

Min Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-10-30
Primary Completion
2022-09-30
Completion
2022-09-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04078178 on ClinicalTrials.gov